Physician profile
Pragathi Challa
NPI 1033116066
$3,853.15
in general payments reported to CMS, 2019-2025
29 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $95.04 · 2021: $424 · 2022: $1,039 · 2023: $693 · 2024: $774 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,008.21 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $596.41 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $293.49 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $272.84 | 2020-2025 | Spravato, Xarelto |
| Novo Nordisk INC | $254.00 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $181.56 | 2022-2024 | Trelegy Ellipta |
| Astellas Pharma US INC | $140.35 | 2021-2023 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $139.24 | 2021-2023 | Eliquis |
| Radius Health, INC. | $133.66 | 2024-2025 | Tymlos |
| Pfizer INC. | $87.53 | 2022-2025 | |
| Exact Sciences Corporation | $86.63 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amarin Pharma, INC. | $74.99 | 2019 | |
| Lilly USA, LLC | $71.52 | 2021-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $70.79 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $70.26 | 2024-2025 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $69.08 | 2021-2024 | Prolia, Evenity, Repatha |
| Abbott Laboratories | $52.31 | 2021-2023 | Freestyle Libre 3 |
| Abbvie INC. | $44.85 | 2023-2025 | Ubrelvy |
| Mylan Specialty L.P. | $26.73 | 2023-2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $24.92 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $22.68 | 2022 | |
| Inspire Medical Systems, INC. | $19.16 | 2024 | Inspire |
| Esperion Therapeutics, INC. | $19.11 | 2021 | |
| Corcept Therapeutics | $18.88 | 2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $18.87 | 2021 | |
| Csl Behring | $14.82 | 2020 | |
| Currax Pharmaceuticals LLC | $14.04 | 2025 | Contrave |
| Ibsa Pharma INC. | $13.76 | 2025 | Licart, Flector, Tirosint |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pragathi Challa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.